Xentuzumab manufacturers
- Xentuzumab
-
- $1450.00
-
2026-07-27
- CAS:1417158-65-6
- Purity: 95.21%
- Supply Ability: 10g
|
| | Xentuzumab Basic information |
| Product Name: | Xentuzumab | | Synonyms: | Xentuzumab;Research Grade Xentuzumab;Xentuzumab (anti-IGF1);BI 836845 | | CAS: | 1417158-65-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Xentuzumab Structure]() |
| | Xentuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Xentuzumab Usage And Synthesis |
| Uses | Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation[1]. | | in vivo | Xentuzumab (200 mg/kg i.p., once weekly for 10 weeks) in inhibits tumor growth in LuCaP 96CR patient-derived xenograft model in mice[1].
| Animal Model: | Fox Chase CB17 severe combined immunodeficiency (SCID; CB17/lcr-Prkdc scid/lcrlcoCrl) male mice with LuCaP 96CR cell (s.c.)[1] | | Dosage: | 200 mg/kg | | Administration: | Intraperitoneal injection; once weekly for 10 weeks; sacrificed 6 hours after the last dose | | Result: | Resulted in significant reductions in tumor volume. |
| | References | [1] Weyer-Czernilofsky U, et al. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Mol Cancer Ther. 2020 Apr;19(4):1059-1069. DOI:10.1158/1535-7163.MCT-19-0378 |
| | Xentuzumab Preparation Products And Raw materials |
|